Alpha memo: resveratrol exercise training cross-context evidence signal

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Rephrase any 'resveratrol blunts' claims to make clear this is the source's framing/title claim, and report the actual between-arm effect size comparison from Receipt 2 (or explicitly note it is not extracted in this bundle).
2. Add a one-sentence note that the two receipts share only the resveratrol-plus-exercise pairing but not the species, tissue, endpoint family, or dose, which is the reason the 'split' is best read as a context-divergence signal rather than a head-to-head contradiction.
3. Consider including a third receipt (e.g., a human resveratrol-plus-exercise trial in a different population or endpoint) to strengthen the cross-context claim, or narrow the title to 'two-receipt cross-context divergence signal' to avoid implying a broader pattern.

Major issues

• Receipt 2 is mischaracterized: the source title is 'Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men,' but the manuscript describes a 45% increase and the source excerpt actually states 'Exercise training led to a 45...' — the memo asserts resveratrol 'blunts' the gains without specifying that the abstract/source framing of blunting is being treated as a given, and the memo does not report the actual effect size difference between the resveratrol and placebo arms. The 'blunting' characterization needs to be presented as a direct source claim, not an independent assertion, and the manuscript should note the actual between-group contrast available in the source.
• Receipt 1 is mechanistic (mouse, intestine, Nrf2/ferroptosis) and Receipt 2 is human cardiovascular. The memo's central 'alpha' — that the same combined intervention 'splits by species, tissue, and endpoint rather than replicating as a single transferable benefit' — is a weak signal because the two studies measure fundamentally different things. The memo should more explicitly acknowledge this is a cross-context comparison with minimal shared outcome infrastructure, not a contradiction test.

Minor issues

• Receipt 1 evidence_type is 'primary' but is an animal mechanistic study; Receipt 2 is human RCT — the memo could note this evidence-type asymmetry more prominently.
• The one-sentence alpha would benefit from stating the specific endpoints more concretely (intestinal Nrf2/ferroptosis markers vs cardiovascular parameter).
• The falsifier paragraph is good but could be tightened to remove redundancy with the caveats list.
• No 45% figure is attributed to which cardiovascular parameter in the source; if the source specifies (e.g., MAP, VO2max), the memo should name it.

Reviewer note

The memo is well-structured, source-grounded, and appropriately bounded. Both cited receipts exist and directly support the two evidence anchors. The title/section alignment is good — resveratrol + exercise training is the consistent anchor across both receipts, and the species/tissue/endpoint divergence is explicit. Limitations are strong and concrete, including a falsifier paragraph. The main issue is that the 'blunting' characterization in Receipt 2 is treated as established fact when the memo's source bundle does not extract the actual between-arm effect sizes; the source title carries the blunting framing, and this should be flagged as such. Additionally, the central claim of a 'split' rests on two studies that share almost no methodological infrastructure, which is a mild overclaim given the bundle size. Recommend revise to (1) clarify blunting is a source framing, (2) note the methodological non-overlap more prominently, and (3) optionally add a third receipt or narrow the scope claim.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis